|Year : 2021 | Volume
| Issue : 5 | Page : 439-441
News Update on the Asia-Pacific Journal of Oncology Nursing
Winnie KW So
Editor-in-Chief, Asia-Pacific Journal of Oncology Nursing
|Date of Submission||26-Jul-2021|
|Date of Acceptance||28-Jul-2021|
|Date of Web Publication||27-Aug-2021|
Winnie KW So
The Nethersole School of Nursing, The Chinese University of Hong Kong, Hong Kong
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
So WK. News Update on the Asia-Pacific Journal of Oncology Nursing. Asia Pac J Oncol Nurs 2021;8:439-41
I am very delighted to provide you with an update on the Asia-Pacific Journal of Oncology Nursing (APJON).
| APJON Received its First Impact Factor in 2021 and will Develop Further in 2022|| |
Since its establishment in 2014, APJON has served as the official journal of the Asian Oncology Nursing Society and has provided an important platform for addressing a wide spectrum of issues related to oncology nursing and cancer care for cancer patients. This year is particularly special for APJON as it received its first impact factor of 2.509 and ranked in the top 25% (Q1) of the journals in the nursing category. This achievement is the result of the dedication of the entire APJON team, including the managing editor Dr. Kevin Liu, the editorial board members who are well-known nursing and health-related experts from 23 countries and regions, the journal reviewers and our publisher Wolters Kluwer-Medknow. Our high-quality articles have proven to be informative and beneficial to readers. In the past 7 years, APJON has published 419 articles, including original articles, reviews, and editorials, covering a wide spectrum of health issues across the cancer continuum. I would like to thank all of the authors who have submitted their research to APJON. The total number of views on APJON's full-text articles increased from 26,852 in 2015 to 260,784 in 2020. The top five most cited articles published in the journal belong to the fields of immunotherapy and related management and care for cancer patients, tool validation, innovative interventions for caregivers of cancer patients, and supportive care needs of caregivers of cancer patients. This reflects the readers' eagerness to learn about contemporary cancer treatment and management as well as evidence-based approaches to address the needs of caregivers of cancer patients. Due to the increasing number of high-quality manuscripts received, APJON has grown from a quarterly journal in 2014 to a bimonthly journal in 2021 and will soon transition into a monthly journal in 2022. The journal will also work with a new publisher, Elsevier, in 2022. I would like to take this opportunity to thank Wolters Kluwer-Medknow for promoting APJON over the past 7 years. I hope that APJON continues to grow and becomes one of the world's leading journals in the field of oncology. Let us work together to reach greater heights.
I am very pleased to inform you that Dr. Linda Krebs and Dr. Tateaki Naito have been appointed as associate editors of APJON and that Dr. Shengfeng Wang, Dr. Lei Yang, Dr. Akifumi Notsu, and Dr. Keita Mori have joined us as biostatistics consultants. Dr. Qiaohong Guo and Dr. Ruishuang Zheng have joined us as a new editorial board member and an assistant editor, respectively.
Dr. Linda U. Krebs, PhD, RN, AOCN, FAACE, FAAN, is an associate professor emerita at the University of Colorado College of Nursing, the President/CEO of the Oncology Consultation, Education and Advocacy Network, and the Vice President of Native American Cancer Initiatives, Inc. Dr. Krebs works collaboratively with Native American Cancer Research Corporation in Denver, Colorado, to enhance the quality of life of Native Americans and medically un/underinsured cancer patients. She has extensive experience in oncology nursing and in oncology education for both health-care providers and the public, owing to her past roles as an oncology clinical nurse specialist, a cancer screening practitioner, and an oncology nurse consultant/educator. Specifically, she has provided education and mentorship on patient navigation, patient teaching and expert cancer care in both community and professional settings. Dr. Krebs has also served as a Core Member of the National Cancer Institute's Central Institutional Review Board, as a Principal Investigator or Co-Investigator for numerous locally and federally funded cancer-related projects, as Conference Management Portfolio Chair for the International Society of Nurses in Cancer Care and as the National President of the Oncology Nursing Society.
Dr. Tateaki Naito, MD, PhD, is a chief physician of the Division of Thoracic Oncology at the Shizuoka Cancer Center, Japan. He obtained his MD license in 1997 and completed his PhD from the Hamamatsu University in 2007. His main interests are clinical research in supportive cancer care, especially for cancer cachexia and thoracic cancer. He is currently serving as Vice-Chair of the Nutrition and Cachexia study group in the Multinational Association of Supportive Care in Cancer and the Japanese Association of Supportive Care in Cancer. In addition, he is involved in the execution of multiple clinical trials of a multimodal program for cancer cachexia in Japan. The program combines nutritional counseling, home-based resistance training, and nurse-led physical activity counseling to promote behavioral changes in daily activity based on the analysis of pedometer data. Through these activities, he contributes to the education of oncology nurses and promotes nurse-led research in medical oncology.
Dr. Shengfeng Wang, MD, PhD, is an assistant professor and a doctoral tutor of epidemiology and biostatistics at Peking University. He received a Bachelor's degree in medicine in 2007 and completed his PhD in epidemiology and biostatistics in 2012 at Peking University. He served as a visiting scholar in the Pritzker School of Medicine, University of Chicago, from 2015 to 2017. As a principal investigator, he has conducted several real-world studies in the fields of pharmacology (e.g. adverse drug reactions) and oncology (e.g. breast cancer and cervical cancer), focusing on estimating the disease burden, identifying the risk factors and establishing related prediction models to facilitate clinical practice.
Dr. Lei Yang, PhD, is an assistant professor of cancer epidemiology at the Peking University Cancer Hospital. Dr. Yang graduated in epidemiology and biostatistics from Peking University, Beijing, China, in 2010. He then joined the Peking University Cancer Hospital and served as a registrar at the Beijing Cancer Registry. His main work was to collect and perform quality control of the incidence and mortality data of cancer in Beijing between 2010 and 2014. Furthermore, since 2014, he has been involved in a large-scale cancer screening program in Beijing, China. His research focuses on developing cost-effective risk assessment tools for population-based precision cancer screening and surveillance. His current research, which is supported by the Beijing Cancer Institute, aims to translate epidemiologic advances into clinical practice for improved cancer prevention and treatment. Dr. Yang was awarded the Beijing Young Talent Award by the Beijing Municipal Government in 2016. He is also a committee member of the Reproductive Medicine Branch of the Chinese Preventive Medicine Association. He has published more than 30 scientific articles.
Dr. Akifumi Notsu, PhD, is a biostatistician in the Clinical Research Center, Shizuoka Cancer Center, Japan. He completed his PhD in statistical science from the Graduate University for Advanced Studies in 2014. He served as a lecturer in statistics at the Oita University of Nursing and Health Sciences, Japan, for 4 years and supported nursing research. He has contributed to the planning, execution, and analysis of multiple clinical trials of pharmacological and nonpharmacological interventions in oncology or supportive cancer care at the Shizuoka Cancer Center. Recently, he coauthored nursing research papers in APJON about end-of-life care in cancer patients. Through these activities, he contributes to the biostatistics education of oncology nurses and promotes nurse-led research in medical oncology.
Dr. Keita Mori, PhD, is the chief biostatistician of the Department of Biostatistics in the Clinical Research Support Center at the Shizuoka Cancer Center, Japan. He completed his PhD in statistical science at the Graduate University for Advanced Studies, SOKENDAI in 2014. He has nearly 10 years of experience as a trial statistician and investigator in clinical oncology. He recently served as a member of the Executive Committee and of the Scientific Advisory Board of the Japan Supportive Palliative and Psychosocial Oncology Group. Through these activities, he contributes to the biostatistics education of doctors, nurses, physiotherapists, dietitians, psychologists, and basic researchers and promotes clinical trials in the field of medical oncology.
Dr. Qiaohong Guo is an associate professor at the Capital Medical University School of Nursing, a member of the Honor Society of Nursing, Sigma Theta Tau International and the International Psycho-Oncology Society Palliative Care Research Subcommittee, a Vice-Chairman of the Palliative Care Council of China Association of Gerontology and Geriatrics and the Youth Committee of Nursing of Academic Committee of the Cancer Rehabilitation Society of the Chinese Anti-cancer Association, a committee member of the China Anti-Cancer Association Psycho-Oncology Society and the Chinese Association for Humanistic & Palliative Care. Her research interests concern psychosocial issues in hospice palliative care and family-based interventions for advanced cancer patients. She has been actively engaging in palliative oncology research in China, USA and Canada. Her work was funded by the National Natural Science Foundation of China, Beijing Social Science Young Scientists Fund, Chinese Medical Association, Sigma Theta Tau International and Manitoba Health Research Council/Research Manitoba. She is a reviewer for 11 SCI journals, and was a section editor for the Annals of Translational Medicine. She also serves as an expert member for the Hospice Care Program of Beijing Municipal Health Commission.
Dr. Ruishuang Zheng is a registered nurse in the Department of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute & Hospital and National Clinical Research Center for Cancer. She has more than ten years of nursing experience in cancer care of general acute settings. She received her PhD. from Monash University in 2021 at Melbourne, Australia, and her MSN from Central South University in 2011 at Changsha, China. Her primary research interests relate to end of life care and palliative care in acute care environments, including preparedness of nurses to deal with dying and death, communication between nurses and with family members, bad information disclosure and cancer symptom management. Ruishuang's work focuses on adults and family members, nurses, and physician populations in acute care and rehabilitation. Her knowledge areas include mixed methods, qualitative research methods, quantitative research methods, systematic reviews, end-of-life care and palliative care. Till now, her work has resulted in nearly 50 peer-reviewed research publications. Recently, Ruishuang received the 14th Five-Year-Plan Young Talent Special Fund from Tianjin Medical University Cancer Institute & Hospital, which would promote her professional development in end-of-life care.
The list of Editorial Board members is now available on the journal webpage at https://www.apjon.org/editorialboard.asp. Please welcome Linda, Tateaki, Shengfeng, Lei, Akifumi, Keita, Qiaohong, and Ruishuang on board. I look forward to working with all of them.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.